Agios Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Key 2017 Milestones
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Janney Montgomery Scott Upgrades Agios Pharma (AGIO) to Buy
February 16, 2017 1:39 PM ESTJanney Montgomery Scott earlier upgraded Agios Pharma (NASDAQ: AGIO) from Neutral to Buy with a price target of $57.00.
For an analyst ratings summary and ratings history on Agios Pharma click here. For more ratings news on Agios Pharma click here.
Shares of Agios Pharma closed at $46.12 yesterday.
... MoreAgios Pharma (AGIO) Tops Q4 EPS by 17c
February 16, 2017 7:04 AM ESTAgios Pharma (NASDAQ: AGIO) reported Q4 EPS of ($1.34), $0.17 better than the analyst estimate of ($1.51). Revenue for the quarter came in at $22.65 million versus the consensus estimate of $10.89 million.
"Our 2016 accomplishments, including the enasidenib NDA submission with our collaboration partner Celgene and clear proof-of-concept... More
